Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$0.17
-11.0%
$1.62
$0.16
▼
$3.60
$12.30M0.511.19 million shs632,620 shs
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$0.82
-5.5%
$0.98
$0.77
▼
$1.84
$13.07M0.57152,107 shs112,932 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$1.26
-5.3%
$2.64
$1.26
▼
$20.30
$12.85M0.4472,340 shs24,099 shs
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
$1.38
-6.8%
$1.98
$1.39
▼
$5.64
$3.27M1.52609,238 shs1,354 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-0.57%-11.33%-90.41%-93.88%-87.53%
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-0.80%-5.34%-1.23%-39.08%-19.16%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-7.64%-5.67%-42.42%-70.83%-95.35%
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
-1.62%-7.62%-21.91%-45.50%-88.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$0.17
-11.0%
$1.62
$0.16
▼
$3.60
$12.30M0.511.19 million shs632,620 shs
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$0.82
-5.5%
$0.98
$0.77
▼
$1.84
$13.07M0.57152,107 shs112,932 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$1.26
-5.3%
$2.64
$1.26
▼
$20.30
$12.85M0.4472,340 shs24,099 shs
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
$1.38
-6.8%
$1.98
$1.39
▼
$5.64
$3.27M1.52609,238 shs1,354 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-0.57%-11.33%-90.41%-93.88%-87.53%
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-0.80%-5.34%-1.23%-39.08%-19.16%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-7.64%-5.67%-42.42%-70.83%-95.35%
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
-1.62%-7.62%-21.91%-45.50%-88.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
1.71
Reduce$1.00481.40% Upside
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
2.00
Hold$10.251,154.59% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
2.25
Hold$17.001,249.21% Upside
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest XTLB, ALLR, MCRB, and ABOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
UpgradeSell (E+) ➝ Sell (D-)
11/12/2026
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
UpgradeSell (E+) ➝ Sell (D-)
11/2/2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
Lower Price TargetBuy$1.00
11/2/2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
DowngradeStrong-Buy ➝ Hold
11/2/2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
DowngradeBuy ➝ Underperform$1.00
10/30/2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
DowngradeSell (D-) ➝ Sell (E+)
10/30/2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
DowngradeStrong-Buy ➝ Strong Sell
10/30/2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
DowngradeBuy ➝ Hold$1.00
10/30/2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
DowngradeBuy ➝ Hold$1.00
10/15/2026
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
Reiterated RatingSell (E+)
10/2/2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
Reiterated RatingSell (D-)
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/A$0.48 per shareN/A
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$320K40.85N/AN/A($0.14) per share-5.84
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$789K16.28$0.95 per share1.33$2.10 per share0.60
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
$450K7.27N/AN/A($0.11) per share-12.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$121.33M-$1.54N/AN/AN/AN/A-166.49%-90.79%N/A
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$11.23M-$0.98N/AN/AN/AN/A-349.08%-55.91%N/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$5.70M-$5.00N/AN/AN/A-2,209.55%-194.42%-58.15%N/A
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
-$6.97M-$0.64N/AN/AN/AN/AN/AN/AN/A

Latest XTLB, ALLR, MCRB, and ABOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/18/2026Q2 2026
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
N/A-$0.05N/A-$0.05N/AN/A
11/13/2026Q3 2026
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$0.21-$0.39-$0.18-$0.39$0.01 million$0.01 million
11/4/2026Q3 2026
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$1.00-$1.63-$0.63-$1.63$6.35 million$0.59 million
10/26/2026Q3 2026
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.3886-$0.35+$0.0386-$0.35N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/AN/A
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.17
1.89
1.89
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/A
0.91
1.11
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
1.65
1.65
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
71.01%
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
11.53%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
4.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
6172.33 million64.95 millionOptionable
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
816.00 million15.97 millionNot Optionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
6610.20 million9.67 millionOptionable
XTL Biopharmaceuticals Ltd. stock logo
XTLB
XTL Biopharmaceuticals
102.37 million1.68 millionNot Optionable

Recent News About These Companies

XTL Completed the Acquisition of Psyga Bio Ltd.
XTL Biopharmaceuticals Ltd ADR XTLB
XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Announces ADS Ratio Change

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acumen Pharmaceuticals stock logo

Acumen Pharmaceuticals NASDAQ:ABOS

$0.17 -0.02 (-11.02%)
As of 11:08 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Allarity Therapeutics stock logo

Allarity Therapeutics NASDAQ:ALLR

$0.82 -0.05 (-5.55%)
As of 11:06 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$1.26 -0.07 (-5.26%)
As of 11:08 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

XTL Biopharmaceuticals stock logo

XTL Biopharmaceuticals NASDAQ:XTLB

$1.38 -0.10 (-6.76%)
As of 10:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.